UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): ~~November~~December 1824, 2008

Memory Pharmaceuticals Corp.
__________________________________________
(Exact name of registrant as specified in its charter)


Delaware	000-50642	04-3363475
_____________________ (State or other jurisdiction	_____________ (Commission	______________ (I.R.S. Employer
of incorporation)	File Number)	Identification No.)

100 Philips Parkway, Montvale, New Jersey		07645
_________________________________ (Address of principal executive offices)		___________ (Zip Code)


Registrant’s telephone number, including area code:		(201) 802 - 7100

Not Applicable
______________________________________________
Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Top of the Form

Item 8.01 Other Events.

On ~~November~~December 1924, 2008, Memory Pharmaceuticals Corp. (the "Registrant"), ~~announced~~issued a press release announcing that itthe Registrant has ~~achieved~~dosed the ~~enrollment~~first ~~goal~~patient ~~for~~in its Phase 2 ~~trial~~clinical study of the effect of R3487/MEM 3454, ~~its~~a ~~lead~~nicotinic alpha-7 ~~nicotinic~~partial ~~receptor~~ agonist, inon ~~cognitive~~electrophysiological ~~impairment~~biomarkers ~~associated~~in patients with schizophrenia ~~(CIAS)~~. The ~~Registrant~~study ~~reported~~will ~~that~~evaluate ~~it has randomized 212 patients in~~ the ~~Phase~~effect 2of ~~trial,~~four ~~triggering~~doses aof ~~$5.0~~R3487/MEM ~~million~~3454 ~~payment~~on ~~from~~electrophysiological ~~its~~biomarkers ~~partner~~(such ~~Roche~~as ~~under~~P50 ~~the~~sensory ~~terms~~gating) ~~of the parties Nicotinic Alpha-7 Agonist Agreement. The Registrant reported~~ that ithave ~~expects~~been shown to ~~report~~be ~~top-line~~closely ~~results~~associated ~~from~~with ~~the trial by the end of April 2009~~schizophrenia. A copy of the press release that includes this announcement is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

99.1 Press release dated ~~November~~December 1924, 2008.

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Memory Pharmaceuticals Corp.
November 19, 2008	By:	Jzaneen Lalani
December 24, 2008	By:	/s/ Jzaneen Lalani
		Name: Jzaneen Lalani
		Title: General Counsel

Top of the Form

Exhibit Index

Exhibit No.		Description
99.1		Press Release ~~Dated~~dated ~~November~~December 1924, 2008

Filing Compare · MEMORY PHARMACEUTICALS CORP